AmerisourceBergen Launches $150M Venture Capital Fund
New venture capital fund AB Health Ventures will partner with innovative startup companies in transforming healthcare
AmerisourceBergen (Conshohocken, PA) has announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally.
AB Health Ventures will initially launch with $150 million allocated for investment in early-to mid-stage health-related startups around the world. The fund will prioritize investments in entrepreneurs who are pursuing bold ideas in areas such as the future of pharmacy and distribution, clinical development and commercialization of pharmaceuticals, practice solutions for healthcare providers, and animal health.
AB Health Ventures is a wholly-owned subsidiary of AmerisourceBergen that “will utilize the company‘s deep expertise, global footprint, and strong relationships with stakeholders across the pharmaceutical supply chain to add value to entrepreneurs looking for partners to help grow their businesses,” the company reports. AmerisourceBergen will support startups in helping them rapidly prototype solutions, test with pilots, and accelerate scale through commercialization.
For more information, visit www.abhealthventures.com
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
